Chimeric antigen receptor (CAR)-engineered T cells have demonstrated remarkable success in the treatment of B cell malignancies. FDA approval of these therapies represents a watershed moment in the development of therapies for cancer. Despite the successes of the last decade, many patients will unfortunately not experience durable responses to CAR therapy. Emerging research has shed light on the biology responsible for these failures, and further highlighted the hurdles to broader success. Here, we review the recent research identifying how interactions between cancer cells and engineered immune cells result in resistance to CAR therapies.

中文翻译：

---

CAR T细胞疗法耐药机制。

嵌合抗原受体 (CAR) 工程化 T 细胞在治疗 B 细胞恶性肿瘤方面取得了显著成功。FDA 批准这些疗法代表了癌症疗法发展的分水岭。尽管过去十年取得了成功，但不幸的是，许多患者不会对 CAR 疗法产生持久的反应。新兴研究揭示了造成这些失败的生物学原因，并进一步突出了更广泛成功的障碍。在这里，我们回顾了最近的研究，该研究确定了癌细胞和工程免疫细胞之间的相互作用如何导致对 CAR 疗法的抵抗。